Clinical Trials on Secondary Hyperparathyroidism Due to Renal Causes in Hong Kong

Total 5 results

The University of Hong Kong
AbbVie

Unknown

Intravenous Paricalcitol in Chronic Hemodialysis Patients

Secondary Hyperparathyroidism | Endstage Renal Disease

Hong Kong
The University of Hong Kong

Completed

Cinacalcet Versus Parathyroidectomy in Peritoneal Dialysis Patients (PROCEED)

Vascular Diseases | Secondary Hyperparathyroidism | Kidney Failure

Hong Kong
OPKO Health, Inc.

Active, not recruiting

Safety, Efficacy, PK and PD of CTAP101 (Calcifediol) ER Capsules for SHPT in HD Patients VDI

Chronic Kidney Diseases | Vitamin D Deficiency | Stage 5 Chronic Kidney Disease | Secondary Hyperparathyroidism Due to Renal Causes

United States
Amgen

Completed

Head-to-Head Study of Etelcalcetide and Cinacalcet in Asian Hemodialysis Patients With Secondary Hyperparathyroidism (SHPT)

Chronic Kidney Disease | Secondary Hyperparathyroidism

Korea, Republic of, Taiwan, Hong Kong, China, India, Malaysia
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Ranibizumab 0.5 vs Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia (Brilliance)

Visual Impairment Due to Choroidal Neovascularization (CNV) Secondary to Pathologic Myopia (PM)

China, India, Thailand, Hong Kong, Korea, Republic of, Philippines

3

Subscribe